At-risk patients include neonates, patients with indwelling catheters and patients undergoing certain types of surgery. The phase I study will evaluate safety and immune response of the vaccine
Under the terms of the proposed acquisition, Chromos will issue approximately 20.1 million common shares as consideration to Targeted Molecules Corporation (TMC) shareholders During the acquisition process and
If licensed, Fluarix will be used for the active immunization of adults against influenza disease caused by influenza virus types A and B contained in the vaccine. Fluarix
The National Institutes of Health (NIH) license covers a DNA plasmid developed by scientists from the National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC).
In the study, children use a nebulizer to inhale cisplatin, a standard cancer drug that has been specially encapsulated in protective fatty protein bubbles. As it the drug
In October 2004, the FDA placed the TNFerade clinical program on hold after blood clots were observed in patients with esophageal cancer in a separate phase II trial.
The new drug application (NDA) contains the largest database ever assembled in a regulatory filing for pulmonary arterial hypertension (PAH), with approximately 900 PAH patients receiving Thelin (sitaxsentan)
Alnylam will apply RNAi technology to the discovery of short interfering RNAs (siRNAs), the active molecules of RNA interference (RNAi), that target key flu genes required for virus
Data also showed there was no evidence of tolerance over the three-month treatment period or withdrawal upon discontinuation of treatment – complications often seen with extended use of
Under the terms of the agreement, Isis will receive a technology access fee of $1 million, research funding, and milestone payments. In addition, Isis will receive royalties on
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.